Form 8-K · Current report
Abbott Laboratories 8-K, filed Aug 20, 2026
- Filed
- CIK
- 0000001800
- Accession no.
- 0001104659-26-099247
Summary
Abbott Laboratories has agreed to pay approximately $670 million to settle the Gill preterm-infant-formula lawsuit and necrotizing enterocolitis (NEC) claims brought on behalf of about 2,000 additional infants, after the Missouri Court of Appeals affirmed a $495 million verdict against it; Abbott said the agreements are a compromise of disputed claims and not an admission of liability. Roughly 1,700 lawsuits involving about 12,700 infants remain pending in federal and state courts.
Key points
- Abbott entered agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals for about $670 million, versus roughly $600 million it would have owed on the Gill judgment plus accrued interest.
- A St. Louis jury awarded the Gill plaintiff $495 million in July 2024; Abbott appealed in December 2024 and the Missouri Court of Appeals affirmed in May 2026.
- Abbott cited favorable rulings including a July 2026 Seventh Circuit affirmance of a pretrial judgment in the first federal MDL bellwether case involving its preterm infant formulas, and a June 2026 Illinois Appellate Court reversal of a $60 million verdict against Mead Johnson.
- About 1,700 lawsuits involving approximately 12,700 infants remain pending, including claims naming both Abbott and Mead Johnson without identifying which manufacturer's formula was used and claims involving infants never diagnosed with NEC.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 7.01 Regulation FD Disclosure. On August 20, 2026, Abbott issued a press release announcing the settlement of a portion of its litigation involving its specialty formulas for preterm infants. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.